Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
Human pancreatic ductal adenocarcinoma (PDAC) exhibits marginal responses to anti-PD-1/PD-L1 immunotherapy and its mechanism remains poorly understood. We have investigated the effect of anti-PD-L1 and c-Myc inhibition in PDAC. Using 87 patients with PDAC from our hospital database we found a signif...
Gorde:
| Egile Nagusiak: | , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis Group
2019-05-01
|
| Saila: | OncoImmunology |
| Gaiak: | |
| Sarrera elektronikoa: | http://dx.doi.org/10.1080/2162402X.2019.1581529 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|